Perseveration by NK1R-/- ('knockout') mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test.
The underlying cause(s) of abnormalities expressed by patients with attention deficit hyperactivity disorder (ADHD) have yet to be delineated. One factor that has been associated with increased vulnerability to ADHD is polymorphism(s) of TACR1, which is the human equivalent of the rodent NK1 (substance P-preferring) receptor gene (Nk1r). We have reported previously that genetically altered mice, lacking functional NK1R (NK1R-/-), express locomotor hyperactivity, which was blunted by the first-line treatment for ADHD, methylphenidate. Here, we compared the effects of this psychostimulant (3, 10 and 30 mg/kg, intraperitoneally) on the behaviour of NK1R-/- mice and their wild types in the 5-Choice Continuous Performance Test, which emulates procedures used to study attention and response control in ADHD patients. Methylphenidate increased total trials (a measure of 'productivity') completed by wild types, but not by NK1R-/- mice. Conversely, this drug reduced perseveration by NK1R-/- mice, but not by wild types. Other drug-induced changes in key behaviours were not genotype dependent, especially at the highest dose: for example, % omissions (an index of inattentiveness) was increased, whereas % false alarms and % premature responses (measures of impulsivity) declined in both genotypes, indicating reduced overall response. These findings are discussed in the context of the efficacy of methylphenidate in the treatment of ADHD. Moreover, they lead to several testable proposals. First, methylphenidate does not improve attention in a subgroup of ADHD patients with a functional deficit of TACR1. Second, these patients do not express excessive false alarms when compared with other groups of subjects, but they do express excessive perseveration, which would be ameliorated by methylphenidate.
Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK.
Katharine
K
Pillidge
Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK.
Ashley J
AJ
Porter
Department of Psychiatry, University of California San Diego, La Jolla, CA, USA Research Service, VA San Diego Healthcare System, San Diego, CA, USA.
Jared W
JW
Young
Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK c.stanford@ucl.ac.uk.
S Clare
SC
Stanford
D000818:Animals; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D001522:Behavior, Animal / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000494:pharmacology*; D002755:Choice Behavior / Q000187:drug effects; D003071:Cognition / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005838:Genotype; D007175:Impulsive Behavior / Q000187:drug effects; D007274:Injections, Intraperitoneal; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018040:Receptors, Neurokinin-1 / Q000235:genetics*
D000697:Central Nervous System Stimulants; D018040:Receptors, Neurokinin-1; D008774:Methylphenidate
ADHD; NK1 receptor; false alarms; impulsivity; inattentiveness; perseveration; premature responses